Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

Bibliográfalaš dieđut
Váldodahkkit:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	BMJ Publishing Group 2021

Geahča maid

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
Dahkki: de Vlam, K, et al.
Almmustuhtton: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
Dahkki: de Vlam, K, et al.
Almmustuhtton: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
Dahkki: Taylor, P, et al.
Almmustuhtton: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
Dahkki: Taylor, PC, et al.
Almmustuhtton: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
Dahkki: Dougados, M, et al.
Almmustuhtton: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Dahkki: Iain B McInnes, et al.
Almmustuhtton: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Dahkki: Dougados, M, et al.
Almmustuhtton: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Dahkki: Maxime Dougados, et al.
Almmustuhtton: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
Dahkki: Taylor, PC, et al.
Almmustuhtton: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Dahkki: Coates, L, et al.
Almmustuhtton: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
Dahkki: Kristensen, LE, et al.
Almmustuhtton: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Dahkki: Philip J. Mease, et al.
Almmustuhtton: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Dahkki: Taylor, P, et al.
Almmustuhtton: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
Dahkki: Daniela Graham, et al.
Almmustuhtton: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Dafna D. Gladman, et al.
Almmustuhtton: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Dahkki: Laura C. Coates, et al.
Almmustuhtton: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Dahkki: Peter C. Taylor, et al.
Almmustuhtton: (2022-07-01)

Measuring outcomes in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Dahkki: Alexis Ogdie, et al.
Almmustuhtton: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Dahkki: Lars Erik Kristensen, et al.
Almmustuhtton: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Dahkki: Nash, P, et al.
Almmustuhtton: (2020)

Psoriatic arthritis
Dahkki: FitzGerald, O, et al.
Almmustuhtton: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
Dahkki: Victoria Navarro-Compán, et al.
Almmustuhtton: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
Dahkki: Marta Skorupska, et al.
Almmustuhtton: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
Dahkki: Taylor, PC, et al.
Almmustuhtton: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Dahkki: Philip J Mease, et al.
Almmustuhtton: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Dahkki: Philip J Mease, et al.
Almmustuhtton: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
Dahkki: Taylor, P, et al.
Almmustuhtton: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Dahkki: Kevin L. Winthrop, et al.
Almmustuhtton: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Dahkki: Lars E. Kristensen, et al.
Almmustuhtton: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Dahkki: Nash, P, et al.
Almmustuhtton: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
Dahkki: Burmester, GR, et al.
Almmustuhtton: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Dahkki: Ly K, et al.
Almmustuhtton: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Dahkki: Nash, P, et al.
Almmustuhtton: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Dahkki: Gerd R. Burmester, et al.
Almmustuhtton: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Dahkki: Peter Nash, et al.
Almmustuhtton: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
Dahkki: Leung, Y, et al.
Almmustuhtton: (2018)